PI3K/Akt/mTOR-IN-2

CAS No. 2757804-89-8

PI3K/Akt/mTOR-IN-2( —— )

Catalog No. M35442 CAS No. 2757804-89-8

PI3K/Akt/mTOR-IN-2 is a potent PI3K/AKT/mTOR inhibitor with anticancer effects and selectivity for MDA-MB-231 cells (IC50 2.29 μM). It induces cell cycle arrest and apoptosis in cancer cells.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 80 In Stock
5MG 72 In Stock
10MG 126 In Stock
25MG 269 In Stock
50MG 423 In Stock
100MG 622 In Stock
200MG Get Quote In Stock
500MG 1321 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    PI3K/Akt/mTOR-IN-2
  • Note
    Research use only, not for human use.
  • Brief Description
    PI3K/Akt/mTOR-IN-2 is a potent PI3K/AKT/mTOR inhibitor with anticancer effects and selectivity for MDA-MB-231 cells (IC50 2.29 μM). It induces cell cycle arrest and apoptosis in cancer cells.
  • Description
    PI3K/Akt/mTOR-IN-2 is a PI3K/AKT/mTOR pathway inhibitor. PI3K/Akt/mTOR-IN-2 possess anti-cancer effects and selectivity against MDA-MB-231 cells with IC50 value of 2.29 μM. PI3K/Akt/mTOR-IN-2 can induce cancer cell cycle arrest and apoptosis.
  • In Vitro
    PI3K/Akt/mTOR-IN-2 (compound 23) (0.5 - 100 μM; 72 hours) exhibits effective anti-cancer activity with IC50s of 2.29 - 24.63 μM, of which, IC50 in MDA-MB-231 is 2.29 μM.PI3K/Akt/mTOR-IN-2 (1 μM, 2 μM and 4 μM; 24 hours) induces growth inhibition of MDA-MB-231 cells by cell cycle arrest at G0/G1.PI3K/Akt/mTOR-IN-2 (1 μM, 2 μM and 4 μM; 24, 48 and 72 hours) induces apoptosis in MDA-MB-231 cells with both dose- and time-dependent manners.PI3K/Akt/mTOR-IN-2 (1 μM, 2 μM and 4 μM; 48 hours) increases the expression of Bax, and decreases the expression of Bcl-2 in MDA-MB-231 cells.PI3K/Akt/mTOR-IN-2 (1 μM, 2 μM and 4 μM; 24 hours) induces mitochondria-dependent apoptosis in MDA-MB-231 cells through disruption of MMP, accumulation of ROS, depletion of GSH and elevation of intracellular Ca2+.]Cell Proliferation Assay Cell Line:PC3, BGC-823, A549, MCF-7, MDA-MB-231 cells and MCF-10A cells Concentration:0.5 - 100 μMIncubation Time:72 hoursResult:Exhibited effective anti-cancer activity with IC50s of 2.29 - 24.63 μM, of which, IC50 in MDA-MB-231 was 2.29 μM.Cell Cycle Analysis Cell Line:MDA-MB-231 Concentration:1 μM, 2 μM and 4 μM Incubation Time:24 hours Result:Induced growth inhibition of MDA-MB-231 cells by cell cycle arrest at G0/G1. Apoptosis Analysis Cell Line:MDA-MB-231 Concentration:1 μM, 2 μM and 4 μM Incubation Time:24, 48 and 72 hours Result:Induced apoptosis in MDA-MB-231 cells with both dose- and time-dependent manners.Western Blot Analysis Cell Line:MDA-MB-231 Concentration:1 μM, 2 μM and 4 μM Incubation Time:48 hours Result:Increased the expression of Bax, and decreased the expression of Bcl-2
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    PI3K/Akt/mTOR signaling
  • Target
    mTOR
  • Recptor
    mTOR | Akt | Apoptosis | PI3K
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2757804-89-8
  • Formula Weight
    285.29
  • Molecular Formula
    C17H13F2NO
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : ≥ 100 mg/mL (350.52 mM)
  • SMILES
    Fc1cc(F)cc(c1)C1OCCc2c1[nH]c1ccccc21
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Qin J, Sun X, Ma Y, et al. Design, synthesis and biological evaluation of novel 1,3,4,9-tetrahydropyrano[3,4-b]indoles as potential treatment of triple negative breast cancer by suppressing PI3K/AKT/mTOR pathway [published online ahead of print, 2021 Dec ?
molnova catalog
related products
  • WYE-125132

    A potent, specific, ATP-competitive and orally active mTOR inhibitor with IC50 of 0.19 nM.

  • CNX-2006

    CNX-2006 is a novel irreversible mutant-selective EGFR inhibitor with IC50 of < 20 nM, with very weak inhibition at wild-type EGFR.

  • Protopine

    Protopine is a benzylisoquinoline alkaloid. It has been found to inhibit histamine H1 receptors and platelet aggregation, and acts as an analgesic.